Evidence map›Paper›PMID 31196459›Full record

ReviewJournal of the American College of Cardiology2019

Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review.

Márcio G Kiuchi, Murray D Esler, Gregory D Fink, John W Osborn, Christopher T Banek, Michael Böhm, Kate M Denton, Gerald F DiBona, Thomas H Everett, Guido Grassi and 12 more

Open access · greenAbstract readReview
In one paragraph

Review in Journal of the American College of Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Systematic review of renal denervation for the management of cardiac arrhythmias.Clinical research in cardiology : official journal of the German Cardiac Society · 2022
    Pooled it
  2. Pleiotropic effects of renal denervation beyond blood pressure reduction.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  3. Review
  4. Overcoming variable response in renal denervation: Key strategies for reliable clinical implementation.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Current problems in renal denervation and a hope to break the stage.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Review
  15. Review
  16. Optogenetics supports to identify the function of renal autonomic system.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Article
  17. Renal and hypothalamic inflammation in renovascular hypertension: role of afferent renal nerves.American journal of physiology. Regulatory, integrative and comparative physiology · 2023
    Article
  18. Article
  19. 2022 Renal denervation therapy for the treatment of hypertension: a statement from the Thai Hypertension Society.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 17 institutions in 7 countries.

Márcio G KiuchiDobney Hypertension Centre, School of Medicine-Royal Perth Hospital Unit, University of Western Australia and Departments of Cardiology and Nephrology, Royal Perth Hospital, Perth, Australia.
Murray D EslerNeurovascular Hypertension & Kidney Disease Laboratory and Human Neurotransmitter Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia.
Gregory D FinkDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan.
John W OsbornDepartment of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota.
Christopher T BanekDepartment of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota.
Michael BöhmKlinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany.
Kate M DentonCardiovascular Program, Monash Biomedicine Discovery Institute and Department of Physiology, Monash University, Melbourne, Victoria, Australia.
Gerald F DiBonaDepartment of Internal Medicine and Molecular Physiology and Biophysics, University of Iowa, Carver College of Medicine, Iowa City, Iowa.
Thomas H EverettThe Krannert Institute of Cardiology and Division of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Guido GrassiClinica Medica, Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
Richard E KatholiPrairie Heart Institute at St. John's Hospital, Department of Cardiology, Springfield, Illinois.
Mark M KnuepferDepartment of Pharmacology and Physiology, St. Louis University School of Medicine, St. Louis, Missouri.
Ulla C KoppDepartments of Internal Medicine and Pharmacology, University of Iowa Carver College of Medicine, Iowa City, Iowa.
David J LeferCardiovascular Center of Excellence and Department of Pharmacology, LSU Health Science Center, New Orleans, Louisiana.
Thomas E LohmeierDepartment of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, Missouri.
Clive N MayThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.
Felix MahfoudKlinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany.
Julian F R PatonDepartment of Physiology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand; School of Physiology, Pharmacology & Neuroscience, Biomedical Sciences, University of Bristol, Bristol, United Kingdom.
Roland E SchmiederDepartment of Nephrology and Hypertension, University Hospital of the University Erlangen-Nuremberg, Erlangen, Germany.
Peter R PellegrinoDepartments of Anesthesiology and Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska.
Yehonatan SharabiChaim Sheba Medical Center and Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel.
Markus P SchlaichDobney Hypertension Centre, School of Medicine-Royal Perth Hospital Unit, University of Western Australia and Departments of Cardiology and Nephrology, Royal Perth Hospital, Perth, Australia; Neurovascular Hypertension & Kidney Disease Laboratory and Human Neurotransmitter Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia. Electronic address: markus.schlaich@uwa.edu.au.
Baker Heart and Diabetes Institute · AUUniversitätsklinikum des Saarlandes · DEUniversity of Iowa · USUniversity of Minnesota · USIndiana University School of MedicineJackson Memorial Hospital · USLouisiana State University Health Sciences Center New Orleans · USMichigan State University · USMonash University · AUSaint Louis University · USSt. John's Hospital · USTel Aviv University · ILThe University of Melbourne · AUThe University of Western Australia · AUUniversity of Auckland · NZUniversity of Milano-Bicocca · ITUniversity of Nebraska Medical Center · US

Funding

Skin Sympathetic Nerve Activity and Cardiac ArrhythmiasR42DA043391 · NIDA · ARRHYTHMOTECH, LLC · PI EVERETT, THOMAS H · 2016 to 2017
$1.5M
Renal denervation to treat hypertension: Mechanisms and mediatorsK99HL141650 · NHLBI · UNIVERSITY OF MINNESOTA · PI BANEK, CHRISTOPHER T · 2018 to 2019
$185k
British Heart Foundation RG/12/6/29670NHLBI NIH HHS K99 HL141650NIDA NIH HHS R42 DA043391
6 · The paper itself

Abstract

Three recent renal denervation studies in both drug-naïve and drug-treated hypertensive patients demonstrated a significant reduction of ambulatory blood pressure compared with respective sham control groups. Improved trial design, selection of relevant patient cohorts, and optimized interventional procedures have likely contributed to these positive findings. However, substantial variability in the blood pressure response to renal denervation can still be observed and remains a challenging and important problem. The International Sympathetic Nervous System Summit was convened to bring together experts in both experimental and clinical medicine to discuss the current evidence base, novel developments in our understanding of neural interplay, procedural aspects, monitoring of technical success, and others. Identification of relevant trends in the field and initiation of tailored and combined experimental and clinical research efforts will help to address remaining questions and provide much-needed evidence to guide clinical use of renal denervation for hypertension treatment and other potential indications.

Indexed as

InternationalityBlood PressureBlood Pressure Monitoring, AmbulatoryCongresses as TopicDenervationHumansHypertensionKidneyRandomized Controlled Trials as TopicReview Literature as TopicSympathectomySympathetic Nervous Systemblood pressurecardiovascular diseasehypertensionrenal denervationsympathetic nervous system

Identifiers

PMID31196459
PMCPMC8559770
OpenAlexW2953135705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.